MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
GT Biopharma Retained Earnings 2011-2026 | GTBP
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings GT Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -724 M | -695 M | -682 M | -674 M | -654 M | - | -567 M | -529 M | -268 M | -125 M | -146 M | -113 M | -89.5 M | -89 M | -83.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -83.8 M | -724 M | -388 M |
Quarterly Retained Earnings GT Biopharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -701 M | -698 M | -696 M | -695 M | -691 M | -688 M | -684 M | -682 M | -679 M | -677 M | -675 M | -674 M | -669 M | -662 M | -659 M | -654 M | -635 M | -630 M | -625 M | -596 M | -596 M | -596 M | -596 M | -567 M | -567 M | -567 M | -567 M | -529 M | -529 M | -529 M | -529 M | -269 M | -269 M | -269 M | -269 M | -125 M | -125 M | -125 M | -125 M | -134 M | -134 M | -134 M | -134 M | -113 M | -113 M | -113 M | -113 M | -89.5 M | -89.5 M | -89.5 M | -89.5 M | -89 M | -89 M | -89 M | -89 M | -83.8 M | -83.8 M | -83.8 M | -83.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -83.8 M | -701 M | -392 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B |  USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 22.24 | 2.02 % | $ 3.69 B | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
-642 M | $ 6.51 | -0.76 % | $ 64.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-105 M | - | -52.27 % | $ 4.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 20.99 | -1.04 % | $ 981 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
AstraZeneca PLC
AZN
|
5.3 B | - | - | $ 96.9 B | Britain |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-237 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 2.96 | -0.6 % | $ 4.87 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.15 | -4.38 % | $ 444 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 23.75 | 1.5 % | $ 3.02 B | USA |
 |
Cara Therapeutics
CARA
|
-110 M | - | -3.03 % | $ 260 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.6 | 3.23 % | $ 426 M | Britain |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
-720 M | $ 1.15 | - | $ 14 M | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
-517 M | $ 3.17 | 1.28 % | $ 319 M | USA |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-978 M | - | - | $ 3.45 B | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Codiak BioSciences
CDAK
|
-325 M | - | -55.98 % | $ 2.15 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-1.4 B | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
-326 M | - | -5.16 % | $ 5.39 M | USA |
 |
Cidara Therapeutics
CDTX
|
-611 M | - | - | $ 1.41 B | USA |
 |
ChromaDex Corporation
CDXC
|
-165 M | - | -0.88 % | $ 598 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Caladrius Biosciences
CLBS
|
-548 M | - | -16.75 % | $ 25.8 M | USA |